Stem Cells and Parkinson's

Your story "Stem Cell Researchers Take on Parkinson's" by Laura DeFrancesco1 suggests that opposition to continuing this research on human subjects is confined to politicians opposed to embryo research and people stirred up by the "press maelstrom" following a New York Times article. It is also opposed by many ethical scientists. What principal investigator Curt Freed is doing strikes me as manifestly unethical. He can no longer consider this human research in a state of equipoise--which justi

Written byLawrence Schneiderman
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

What principal investigator Curt Freed is doing strikes me as manifestly unethical. He can no longer consider this human research in a state of equipoise--which justified the risks in the original randomized controlled trial. For now the results are in. Compared to the present standard of care his intervention is more likely to harm than help. Yet, patients who are vulnerable and desperate are being exploited to undergo (and pay for) it.

I do not object to continuing research but I believe that researchers should put an end to this use of human subjects until more fundamental questions are answered. In contrast to the above, I applaud the position of Lorenz Studer, as quoted in your article: "Studer's not ready, though, to start transplanting his embryonic stem cell derived DA neurons into patients because safety and functionality issues remain."

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies